ELPA educational training days in Barcelona
ELPA educational training started on 3rd December.
ELPA members from Bosnia and Herzegovina, Cyprus, Croatia, Denmark, Finland, Georgia, Ireland, Israel, Macedonia, Norway, Portugal, Romania, Russia, Spain, Serbia, Slovakia, Slovenia, Sweden, the UK, and Turkey had the possibility to hear speakers presenting some inspiring project and to debate amongst them.
GILEAD was the first company presenting. Ms. Hulda Ragnheiður Friðriksdóttir firstly gave an overview of the TraP Hep C Program in Iceland over the period 2016-2019. The program had 3 targets: maximizing the treatment compliance, maximizing the number of patients accepting treatment and minimizing reinfections, taking into account diagnosis and diagnosed people. In addition, thanks to open testing days arranged in hospitals and clinics and to campaigns on TV, radio and social media, screening raised about 80% in Iceland during the past years. She also presented some strategies to increase adherence and maximize treatment uptake. The presentation was followed by an interesting debate on best practices from other countries.
GILEAD team introduced NASH goals in 2020 and presented the GILEAD hepatic fibrosis program. Then they added some goals and approach to evaluation of different programs they run and they presented clinical data that was already presented at AASLD and EASL conferences. We also discussed the conference in Valencia organized by GILEAD in 2019 – Screening and Linkage to Care (SLTC) Summit and the plans for 2020.
The second day of ELPA educational training programme on 4th December started with three presentations. The first one by Dr.Eduardo Espinet, team member on Endoscopic bariatric surgery. He presented the Intragastric Balloon: the procedure, pros and cons, results and follow up. The second one was delivered by Dr. Teresa Casanovas Taltavull. She talked about some updates on hepatocellular carcinoma (HCC) management and a review of the New EASL Guidelines. The last one, by Dr. Viktor Isjanovski, was about psychiatric disorders in liver patients.
The afternoon was characterized by ELPA Team showing ELPA research projects for 2020 and beyond.
During the last day, on 5th December, INTERCEPT was the third company presenting. They stressed the importance of having a multidisciplinary team and introduced the 2020 INTERCEPT advocacy policy. Then, they set up a round table about how improving together NASH care in Europe from the perspective of liver patients.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.